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1511can be used (3). Although effective and with comparable
results to TF-TAVR, the TA-TAVR is associated with well-
described procedural and post-operative risks because it in-
volves a lateral thoracotomy, as well as a left ventricular (LV)
puncture and entrance into the pericardium (4).
New-onset atrial ﬁbrillation (AF) after aortic valve replace-
ment (AVR) has been underappreciated in current guidelines
that report mortality and morbidity after cardiac valve in-
terventions (5). However, recent evidence suggests that the
incidence of AF may be higher than previously expected and
may also be associated with cerebrovascular accidents
(CVAs) after TAVR (6,7). In addition, a higher incidence of
AF has been found in patients who underwent TA-TAVR
(6). The incidence of AF according to various access routes
for TAVR has not been well characterized. We sought to
evaluate the incidence, onset, duration, and predictors of new-
onset AF among patients treated with SAVR and TF-, TA-,
and TAo-TAVR.TA-TAVR = transapical
transcatheter aortic valve
replacement
TAVR = transcatheter aortic
valve replacement
TF-TAVR = transfemoral
transcatheter aortic valve
replacement
TIA = transient ischemic
attackMethods
Patients and procedures. Between March 2010 and
September 2012, a total of 231 consecutive patients under-
went isolated AVR for symptomatic severe degenerative AS
at the University of Miami Hospital. Of these, 82 patients
underwent SAVR and 149 patients underwent TAVR with a
balloon-expandable valve (Edwards SAPIEN, SAPIEN XT,
Edwards Lifesciences, Irvine, California). Patients were
excluded from this analysis if they had a history of either
chronic or paroxysmal AF or any evidence of atrial arrhythmia
in the baseline electrocardiogram (80 patients), a bicuspid
aortic valve (24 patients), or had died within 48 h after the
procedure (4 patients). The ﬁnal study population was 123
patients. TAVR was performed in patients who were deemed
inoperable or had a surgical mortality risk of 15% on the
basis of the consensus of our structural heart disease team.
TF-TAVRwas the preferred access approach in patients with
an appropriate iliofemoral arterial diameter. Otherwise, TA-
or TAo-TAVR was performed. TA-TAVR was performed
using a well-described technique through the LV apex (8).
TAo-TAVR was performed through a mini-upper sternot-
omy and without pericardiotomy (9).
Although the data for this study were retrospectively
collected, all patients followed a pre-speciﬁed clinical and
imaging evaluation at baseline, during hospitalization, and at
30 days. Echocardiographic ﬁndings were analyzed on the
basis of the judgment of full-time academic echocardiog-
raphers, using standard guidelines (10). Comorbidities were
deﬁned according to the Society of Thoracic Surgeons (STS)
criteria, and procedural complications were deﬁned accord-
ing to the Valve Academic Research Consortium Criteria.
Blood transfusion was recorded if the patients received any
blood transfusion related to the procedures, including pre-,
peri-, and post-procedures. CVAs were classiﬁed as transient
ischemic attack (TIA) or stroke. Stroke was further catego-
rized in accordance with the modiﬁed Rankin scale (MRS)as major if the MRS was 2 at
30 days, or minor if the MRS
was <2 at 30 days. All CVAs
were evaluated by a neurologist
and conﬁrmed through neuro-
imaging techniques.
Atrial ﬁbrillation or ﬂutter. Pati-
ents did not receive routine pre-
or peri-operative antiarrhythmic
agents to prevent or decrease the
occurrence of new-onset AF.How-
ever, all surgical patients received
prophylactic atrial pacing for at
least 24 h post-operatively. All pa-
tients were on continuous electro-
cardiographic telemetry monitoring
until hospital discharge. Whenever
an electrocardiographic or cardiac
rhythm abnormality was noted by
either the nursing staff or the
monitoring device, rhythm strips
were printed and attached to the
patient’s chart. In addition, routine
rhythm strips were printed and
charted every 2 h in the cardiac
critical care units, and every 4 h in
the telemetry units, regardless of the
rhythm. A 12-lead electrocardio-
gram was routinely performed pre-operatively, immediately
after the procedure, and on post-operative days 1 and 2. Episodes
of AF or atrial ﬂutter and their respective treatment were
collected by reviewing the electrocardiographic rhythm strips,
12-leadelectrocardiographic tracings,nursingandphysiciannotes,
orders lists, and daily medication lists. Decisions on AF man-
agement, including treatments for rhythm and/or rate control, as
well as anticoagulation, were at the discretion of the primary
cardiologist and/or the cardiothoracic surgeon managing the
patients.
30-day follow-up. A routine clinical follow-up was
scheduled 30 days after the procedure. Patients who were
not able to attend their in-person follow-up visit were
contacted by phone, and their physician’s ofﬁces were con-
tacted to obtain the necessary clinical information, including
vital status, complications, hospitalizations, emergency
department visits, CVAs, and atrial arrhythmias. Date of
CVAs or atrial arrhythmias were noted on the date of
diagnosis. Five patients died before the 30-day follow-up.
Complete follow-up data were available in 92% of patients.
Statistical analysis. Descriptive estimates of the distribu-
tion of each risk factor were compared among the 4 different
approaches. Discrete variables are expressed as frequencies
with their respective percentages. Continuous variables are
presented as mean  SD or median (25th, 75th percentile),
depending on variable distribution. Continuous variables
were compared using the Student t test or Wilcoxon
rank-sum, as appropriate, or 1-way analysis of variance or
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Categorical variables were compared using the chi-square
test or Fisher’s exact test, as appropriate.
Logistic multivariable regression analysis was performed
to identify independent risk factors for AF. We developed 4
multivariable models to examine the association among the
different approaches and AF. Candidate variables were
selected if they had a p value <0.10 in univariate analysis
and a p value <0.10 in the 2 groups’ comparison of each
model. In model 1, we compared each transcatheter
approach versus conventional SAVR, and the variables
entered in the model included STS score, history of chronic
obstructive pulmonary disease, baseline LV hypertrophy on
electrocardiogram, left atrial enlargement, blood transfusion,
and post-procedural leukocytosis. In model 2, we compared
procedures with pericardiotomy (SAVR and TA-TAVR)
versus procedures without pericardiotomy (TF- and TAo-
TAVR), and the variables entered in the model included a
history of chronic obstructive pulmonary disease, the use of
calcium channel blockers, left atrial enlargement, post-
operative peak troponin elevation, and blood transfusion. In
model 3, we compared procedures with thoracotomies
(SAVR and TA- and TAo-TAVR) to purely percutaneous
procedures (TF-TAVR), and the variables entered in the
model included a history of chronic obstructive pulmonary
disease, the use of calcium channel blockers, blood trans-
fusion, bleeding complications, and baseline LV hypertrophy
on electrocardiogram. In model 4, we compared conven-
tional SAVR versus transcatheter procedures (TA-, TAo-,
and TF-TAVR), and the variables entered in the model
included a history of chronic obstructive pulmonary disease,
blood transfusion, bleeding complications, and baseline LV
hypertrophy on the electrocardiogram. All of the models
were well based on the goodness-of-ﬁt test. A 2-sided
p value <0.05 was considered statistically signiﬁcant. All
analyses were conducted using the statistical package SAS,
version 9.2 (SAS Institute, Cary, North Carolina).
Results
AVR was performed using conventional SAVR, TA-, TAo-,
and TF-TAVR in 35, 36, 24, and 28 patients, respectively.
Clinical and electrocardiographic data are shown in Table 1
for the total study population and for each subgroup ac-
cording to the 4 techniques. More than 90% had New York
Heart Association classes III to IV heart failure. The severity
of AS and LV dysfunction were comparable among the
subgroups. Twenty patients (57%) in the SAVR group un-
derwent AVR through a right anterior minithoracotomy.
Patients treated with SAVR had the lowest STS risk scores
(mean  SD) (5.17  2.74), whereas patients treated with
TA-TAVR had the highest STS scores (11.04  3.16).
None of these patients were on antiarrhythmic medications
before the procedure.
Post-procedure hemoglobin levels were higher in patients
who underwent procedures with thoracotomies because themajority of these patients (>90%) received blood trans-
fusions. Post-procedural white blood cell level, a surrogate
for inﬂammatory response, was highest in TA-TAVR and
became signiﬁcantly different among the groups at 24 to 48
and 48 to 96 h. Patients treated with SAVR and TA-TAVR
were more likely to remain intubated for more than 24 h. A
higher incidence of CVAs was observed in patients treated
with TF-TAVR. Other post-procedural complications were
not different among the 4 groups.
Patients with and without new-onset AF. Baseline char-
acteristics among patients with andwithout new-onsetAF are
displayed in Table 2. Patients who developed AF were more
likely to have chronic obstructive pulmonary disease, a higher
use of calcium channel blockers, and electrocardiographic
signs of LV hypertrophy. Left atrial enlargement tended to be
more common in patients with AF. A higher proportion of
patients with new-onset AF received blood transfusions and
also had a higher white blood cell count after the ﬁrst 24 h.
Prolonged intubation was more commonly observed in pa-
tients with AF, whereas need for a permanent pacemaker
secondary to atrioventricular block was less common in these
patients. Patients who developed AF had a longer median
length of stay (9 days; range, 8 to 12 days) compared with
those without AF (6 days; range, 5 to 10 days) (p < 0.01).
Characteristic of new-onset AF. Post-procedural, new-
onset AF occurred in 52 patients (42.27%), with 51 events
occurring during hospital stay (Figs. 1 and 2). The incidence
of new-onset AF varied with the different approaches (Fig. 1,
Online Table A), but the characteristics of new-onset AF
were not signiﬁcantly different among the 4 groups (Fig. 2,
Online Table B). In the immediate post-procedure period, all
patients in the transcatheter group were in normal sinus
rhythm, and those in the SAVR group were atrial-paced.
New-onset AF occurred at a median time of 53 h (25th to
75th percentile, 41 to 87 h), with 41 episodes (78.84%)
occurring between 24 and 96 h after AVR. The median times
of AF onset were 56 h (25th to 75th percentile, 40 to 94 h)
and 52 h (25th to 75th percentile, 40 to 70 h) in the SAVR
and TAVR groups, respectively. More than half of the AF
episodes lasted less than 24 h and spontaneously resolved
without administration of antiarrhythmic agents or electro-
cardioversion. Twenty-ﬁve patients received amiodarone,
including 2 patients who eventually underwent successful
electrocardioversion. Conversion after administration of
amiodarone occurred in the majority of patients who received
the drug, but 11 patients remained in AF at the time of
discharge, and 7 remained in AF at the 30-day follow-up.
Fourteen patients were discharged on amiodarone.
All patients who developed new-onset AF had a
CHA2DS2-VASc score 2, with a median score of 5.5
(5,6). Anticoagulation was initiated during hospitalization in
25 (48.07%) patients. Reasons noted for not administering
anticoagulants were short duration of AF or increased
bleeding risk. In 3 patients, anticoagulation was withheld
due to access site bleeding despite an AF duration more than
48 h. Anticoagulation was initiated at 24 h or more after
Table 1 Population Characteristics
Variables
Total
(N ¼ 123)
SAVR
(N ¼ 35)
TA-TAVR
(N ¼ 36)
TAo-TAVR
(N ¼ 24)
TF-TAVR
(N ¼ 28) p Value*
Clinical characteristics
Age, yrs 84.91  6.92 82.11  8.14 88.28  4.80 84.00  6.47 84.86  6.43 <0.01y
Male 59 (47.96) 19 (54.29) 15 (41.67) 9 (37.50) 16 (57.14) 0.37
Caucasian 113 (98.26) 33 (94.29) 30 (83.33) 24 (100.00) 26 (96.29) 0.42
Hispanic 20 (16.52) 7 (20.00) 3 (8.33) 7 (29.17) 3 (10.71) 0.16
NYHA functional class III–IV 101 (93.51) 29 (85.29) 31 (100.00) 22 (95.65) 19 (95.00) <0.01
STS score 7.67  3.45 5.17  2.74 11.04  3.16 6.60  2.74 8.13  5.26 <0.01y
Medical history
Dyslipidemia 96 (78.05) 29 (82.86) 24 (66.67) 22 (91.67) 21 (75.00) 0.11
Coronary artery disease 84 (67.29) 19 (54.29) 33 (91.67) 14 (58.33) 18 (64.28) <0.01
Peripheral artery disease 46 (37.40) 7 (20.00) 15 (41.67) 17 (70.83) 7 (25.00) <0.01
Hypertension 108 (87.80) 29 (82.86) 31 (88.89) 24 (100.00) 24 (85.71) 0.23
Chronic kidney disease 46 (37.40) 9 (25.71) 14 (38.89) 13 (54.17) 10 (35.71) 0.17
Cerebrovascular disease 34 (27.64) 7 (20.00) 10 (27.78) 8 (33.33) 9 (32.14) 0.64
COPD 46 (37.40) 13 (37.14) 15 (41.67) 13 (54.17) 5 (17.86) <0.01
Diabetes 45 (36.59) 14 (40.00) 10 (27.78) 7 (29.17) 14 (50.00) 0.25
Medication
Beta blocker 71 (57.72) 14 (40.00) 27 (75.00) 17 (70.83) 13 (46.43) <0.01
ACEI/ARB 48 (39.02) 14 (40.00) 13 (36.11) 9 (37.50) 12 (42.86) 0.95
Calcium channel blocker 25 (20.33) 9 (25.71) 10 (27.78) 4 (16.67) 2 (7.14) 0.17
Statins 86 (69.92) 23 (65.71) 23 (63.89) 19 (79.17) 21 (75.00) 0.53
Laboratory investigation
Baseline Cr, mg/dl 1.19  0.40 1.08  0.32 1.24  0.43 1.24  0.36 1.23  0.49 0.31y
Baseline Hb, g/dl 11.77  2.14 12.78  3.26 11.42  1.03 11.24  1.69 11.40  1.38 <0.01*
First 24-h peak Cr, mg/dl 1.28  0.43 1.23  0.44 1.26  0.43 1.30  0.34 1.33  0.51 0.83y
24–48 h peak WBC, 103/ml 12.41  5.05 12.10  4.29 14.32  3.99 12.08  4.53 10.66  6.71 0.03y
24–48 h nadir Hb, g/dl 10.51  1.67 11.07  1.47 10.86  1.52 10.07  1.25 9.75  2.05 <0.01y
48–96 h peak WBC, 103/ml 11.34  4.73 11.73  4.54 13.06  4.41 10.40  3.87 9.40  5.37 <0.01z
48–96 h nadir Hb, g/dl 10.16  1.75 10.77 1.59 10.65  1.45 9.72  1.19 9.13  2.23 <0.01y
Post-operative peak troponin (ng/ml) 3.82  0.44 7.25  4.93 6.02  5.03 2.04  1.70 1.67  3.32 <0.01y
Electrocardiogram
Baseline LVH 21 (17.07) 11 (31.43) 8 (22.86) 1 (4.17) 1 (3.57) <0.01
Echocardiogram
Ejection fraction, % 56.63  12.71 60.71  5.56 56.36  13.08 56.67  11.51 52.86  17.07 0.15y
Mean aortic gradient, mm Hg 44.09  14.76 41.93  14.33 43.88  11.34 45.78  18.26 44.82  16.15 0.83y
Aortic valve area, cm2 0.67  0.19 0.76  0.23 0.63  0.18 0.66  0.17 0.65  0.18 0.08y
Mitral regurgitation 87 (77.00) 20 (71.43) 30 (85.71) 17 (73.91) 20 (74.07) 0.44
Left atrial size
Mild enlargement 44 (37.60) 13 (41.93) 19 (52.78) 4 (18.18) 8 (28.57) 0.02
Moderate and severe enlargement 19 (16.23) 7 (22.58) 6 (16.67) 3 (13.64) 3 (10.71)
Diastolic function 0.14
Grade I 87 (75.00) 24 (80.00) 27 (75.00) 19 (86.36) 17 (60.71)
Grade II–III 23 (19.83) 3 (10.00) 9 (25.00) 2 (9.09) 9 (32.14)
Procedure
Blood transfusion 104 (84.55) 32 (91.43) 35 (97.22) 22 (91.67) 15 (53.57) <0.01
Complications
Required permanent pacemaker 10 (8.13) 2 (5.71) 2 (5.56) 3 (12.50) 3 (10.71) 0.80
Stroke or TIA 5 (4.06) 0 (0.00) 1 (2.78) 0 (0.00) 4 (14.29) 0.02
Renal insufﬁciency 39 (31.70) 9 (25.71) 16 (44.44) 8 (33.33) 6 (21.43) 0.45
Prolonged intubation 38 (30.89) 16 ( 45.71) 16 (44.44) 5 (20.83) 1 (3.57) <0.01
Bleeding 64 (52.03) 18 (51.43) 15 (46.88) 17 (70.83) 14 (50.00) 0.32
Values are n (%) or mean  SD. *Chi-square test. yAnalysis of variance test. zKruskal-Wallis test.
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blockers; Cr ¼ creatinine; COPD ¼ chronic obstructive pulmonary disease; Hb ¼ hemoglobin; LVH ¼ left ventricular hy-
pertrophy; NYHA¼ New York Heart Association functional classiﬁcation; RVSP ¼ right ventricular systolic pressure; SAVR ¼ surgical aortic valve replacement; STS¼ Society of Thoracic Surgeons; TAo-TAVR ¼
transaortic transcatheter aortic valve replacement; TA-TAVR ¼ transapical transcatheter aortic valve replacement; TIA ¼ transient ischemic attack; WBC ¼ white blood cell count.
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Table 2 Population Characteristics: No Atrial Fibrillation (AF) Versus AF
Variables
No AF
(N ¼ 71)
AF
(N ¼ 52) p Value
Clinical characteristics
Age, yrs 84  7.42 86  6.05 0.10
Male 36 (50.70) 23 (44.23) 0.48
Caucasian 67 (98.53) 46 (97.87) 0.34
NYHA functional class III–IV 58 (96.67) 43 (91.49) 0.52
STS score 7.35  3.94 8.13  4.55 0.35
Medical history
Coronary artery disease 51 (71.83) 33 (63.46) 0.32
Peripheral artery disease 28 (39.44) 18 (34.62) 0.59
Hypertension 63 (88.73) 45 (86.54) 0.71
Chronic kidney disease 28 (39.44) 18 (34.62) 0.59
Cerebrovascular disease 19 (26.76) 15 (28.85) 0. 80
COPD 20 (28.17) 26 (50.00) <0.01
Diabetes 31 (43.66) 14 (26.92) 0.06
Medication
Beta-blocker 40 (56.34) 31 (59.62) 0.71
ACEI/ARB 30 (42.25) 18 (34.62) 0.39
Calcium channel blocker 5 (7.04) 20 (38.46) <0.01
Statins 50 (70.42) 36 (69.23) 0.89
Laboratory investigation
Baseline Cr, mg/dl 1.21  0.40 1.16  0.42 0.32
Baseline Hb, g/dl 11.62  1.25 11.97  2.96 0.86
24–48 h peak WBC, 103/ml 11.95  5.46 13.00  4.47 0.04
24–48 h nadir Hb, g/dl 10.16  1.80 10.94  1.37 <0.01
48–96 h peak WBC, 103/ml 10.60  4.63 12.31  4.72 0.05
48–96 h nadir Hb, g/dl 9.76  1.93 10.66  1.35 <0.01
Post-operative peak troponin, ng/ml 3.08  3.79 4.94  5.11 0.07
Electrocardiogram
Baseline LVH 8 (11.44) 13 (25.00) 0.05
Echocardiogram
Ejection fraction, % 55.15  14.24 58.69  10.00 0.31
Mean aortic gradient, mm Hg 44.79  16.06 43.02  12.61 0.99
Aortic valve area, cm2 0.67  0.20 0.68  0.19 0.66
Left atrial size 0.06
Mild enlargement 20 (29.85) 24 (48.00)
Moderate and severe enlargement 9 (13.43) 10 (20.00)
Diastolic function 0.65
Grade I 52 (77.61) 35 (71.43)
Grade II–III 13 (19.40) 10 (20.40)
Procedure
Blood transfusion 57 (80.28) 47 (94) 0.03
Complications
Required permanent pacemaker 7 (9.86) 3 (5.77) 0.04
Stroke or TIA 3 (4.17) 2 (3.92) 0.92
Renal insufﬁciency 19 (26.76) 20 (38.46) 0.36
Prolonged intubation 16 (22.54) 22 (42.31) <0.01
Bleeding 36 (52.94) 28 (57.14) 0.65
Values are n (%) or mean  SD.
Abbreviations as in Table 1.
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(32%) remained on anticoagulation. All anticoagulated pa-
tients received bridging therapy with intravenous unfrac-
tionated heparin.
Predictors of new-onset AF. Clinical factors associated
with the occurrence of new-onset AF were history of chronic
obstructive pulmonary disease, moderate to severe left atrialenlargement, and blood transfusions. However, after
multivariable analysis, none of these factors were indepen-
dently associated with new-onset AF (Table 3).
We identiﬁed a signiﬁcant variation in the incidence of
new-onset AF on the basis of the different procedural
approaches (Table 3). AF occurred in 60% (21 of 35) of
patients who underwent SAVR, in 53% (19 of 36) with
Figure 1 Incidence of New-Onset Atrial FIbrillation in Aortic Valve Replacement
The overall 42% incidence of new-onset AF after AVR (52 of 123 qualifying patients) is subgrouped according to technical factors, speciﬁc procedures (upper left panel), with
pericardiotomy versus nonpericardiotomy (upper right panel), with or without thoracotomy (lower left panel), and surgical versus catheter-based approach (lower right panel).
The incidence was highest with the conventional surgical approach, which corresponded to requirements for chest wall incision and pericardiotomy. Transapical transcatheter
aortic valve replacement (TA-TAVR) also has a higher incidence of new-onset atrial ﬁbrillation than did transaortic transcatheter aortic valve replacement
(TAo-TAVR) or transfemoral transcatheter aortic valve replacement (TF-TAVR). AVR ¼ aortic valve replacement; SAVR ¼ surgical aortic valve replacement.
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1515TA-TAVR, in 33% (8 of 24) with TAo-TAVR, and in 14%
(4 of 28) with TF-TAVR (Fig. 1, Online Table A). By
analyzing according to variations in procedural technical
requirements, we observed that new-onset AF occurred in
56% of those who required pericardiotomy, 51% of those
with thoracotomies and 35% of procedures using the
transcatheter approach. By multivariable analysis, TF-
TAVR was associated with an 82% decrease in the risk of
new-onset AF compared with SAVR (adjusted odds ratio
[AOR]: 0.18; 95% conﬁdence interval [CI]: 0.04 to 0.81),
and procedures without pericardiotomy were associated
with 82% risk reduction (AOR: 0.18; 95% CI: 0.05 to 0.59)
of new-onset AF compared with procedures with peri-
cardiotomy (Tables 3 and 4).
Systemic embolism and cerebrovascular accidents. There
were no episodes of systemic embolism or hemorrhagic
stroke. Five patients developed ischemic CVA after the
procedure: 1 patient in the TA-TAVR group and 4 patients
in the TF-TAVR group (Online Table C). Of these, 3
patients in the TF-TAVR group did not have AF, and the
CVAs occurred at 1, 2, and 5 days after the procedure,
respectively. The other 2 patients developed TIAs at
approximately 1 month after the procedure. Both were in
AF at the time of the diagnosis and were not on anti-
coagulation. The patient treated with TF-TAVR wasdischarged 5 days after the procedure and was diagnosed
with AF and TIA at the 30-day follow-up visit. The patient
treated with TA-TAVR had a post-procedural course
complicated by bleeding and prolonged intubation, had
persistent AF, and was not on anticoagulation at the time of
the TIA diagnosis (day 28).
Discussion
The present study describes the occurrence and character-
istics of new-onset AF in a cohort of elderly patients with
severe symptomatic AS treated with either SAVR or TAVR
using TF-, TA-, or TAo-TAVR approaches. New-onset AF
occurred in 42% of the studied population: 60% in the SAVR
group and 35% in the TAVR groups. Within the TAVR
groups, AF occurred most frequently in TA-TAVR, followed
by TAo- and TF-TAVR, respectively (Fig. 1, Online
Table A). The characteristics of new-onset AF were similar
among each of these subgroups, but we observed signiﬁcant
differences in AF incidence among TAVR patient subgroups,
on the basis of the approach and the need for pericardiotomy.
Although post-operative AF after SAVR has been exten-
sively studied, there are limited data on the occurrence of
new-onset AF following the different TAVR approaches.
TF-TAVR is the only procedure involving percutaneous
Figure 2 Timing and Duration of Post-Procedural Atrial Fibrillation in the Different Approaches
The distribution of times to onset of post-procedural atrial ﬁbrillation is provided in the upper panel. The majority of events occurred between 24 and 96 h after the procedure.
The most common duration of ﬁrst episodes (lower panel) was between 1 and 24 h (Online Table B).
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1516access alone, whereas TA- and TAo-TAVR involve minimal
invasive surgery through left lateral and upper midline tho-
racotomies, respectively. This study demonstrated the differ-
ences in AF occurrence among the various TAVR approaches
compared with traditional SAVR. SAVR was associated
with the highest incidence of AF among the groups studied.
This incidence was higher than the 24% to 49% that wasTable 3 Incidence and Predictors of Post-Procedu
Variables
Nonpericardiotomy vs. pericardiotomy
Procedures with nonpericardiotomy (N ¼ 52)
Nonthoracotomy vs. thoracotomy
Procedures with nonchest wall incision (N ¼ 28)
Catheter approach vs. surgical approach
Procedures with catheter approach (N ¼ 88)
SAVR vs. TA-, TAo-, TF-TAVR
Transapical approach (N ¼ 36)
Transaortic approach (N ¼ 24)
Transfemoral approach (N ¼ 28)
STS score > 10 (N ¼ 33)
History of COPD (N ¼ 46)
Baseline LVH on electrocardiogram (N ¼ 21)
Moderate to severe left atrial enlargement (N ¼ 19)
Blood transfusion (N ¼ 104)
Post-procedural leukocytosis (N ¼ 53)
Values are n (%).
AF ¼ atrial ﬁbrillation; CI ¼ conﬁdence interval; TF-TAVR ¼ transfemoral trareported previously when a right anterior minithoracotomy
was performed (11–13). This was possibly due to the advanced
age, multiple comorbidities, lack of pre-operative pharmaco-
logic interventions, and increased surveillance with contin-
uous telemetry monitoring in our cohort (14).
With regard to the differential incidence of AF associ-
ated with the various transcatheter approaches, the currentlyral Atrial Fibrillation
Incidence of AF
Adjusted Odds Ratio
(95% CI)
12 (23.08) 0.18 (0.05–0.59)
4 (14.29) 0.32 (0.08–1.29)
31 (35.23) 0.64 (0.24–1.70)
19 (52.78) 0.53 (0.17–1.62)
8 (33.33) 0.40 (0.12–1.37)
4 (14.29) 0.18 (0.04–0.81)
19 (57.58) 2.92 (0.94–9.10)
26 (56.52) 2.06 (0.87–4.89)
13 (61.90) 1.39 (0.54–3.59)
10 (52.63) 2.49 (0.98–6.33)
47 (45.19) 1.22 (0.23–6.32)
27 (50.94) 1.66 (0.70–3.97)
nscatheter aortic valve replacement; other abbreviations as in Table 1.
Table 4 Population Characteristics: Pericardiotomy Versus Nonpericardiotomy
Variables
Procedure With Pericardiotomy
(N ¼ 71)
Procedure Without Pericardiotomy
(N ¼ 52) p Value
Clinical characteristics
Age, yrs 85.23  7.30 84.46  6.40 0.53
Male 34 (47.89) 25 (48.08) 0.98
Caucasian 63 (98.44) 50 (98.04) 0.36
NYHA functional class III–IV 60 (84.51) 41 (78.85) 0.85
STS score 7.88  4.15 7.41  4.30 0.28
Medical history
Coronary artery disease 52 (73.24) 32 (61.54) 0.17
Peripheral artery disease 22 (30.99) 24 (46.15) 0.07
Hypertension 60 (84.51) 48 (92.31) 0.19
Chronic kidney disease 23 (32.39) 23 (44.23) 0.18
Cerebrovascular disease 17 (23.94) 17 (32.69) 0.28
COPD 28 (39.44) 18 (34.61) <0.01
Diabetes 24 (33.80) 21 (40.38) 0.45
Medication
Beta-blocker 41 (57.75) 30 (57.69) 0.99
ACEI/ARB 27 (38.03) 21 (40.38) 0.79
Calcium channel blocker 19 (26.76) 6 (11.54) 0.04
Statins 46 (64.79) 40 (76.92) 0.15
Laboratory investigation
Baseline Cr, mg/dl 1.16  0.39 1.23  0.43 0.24
24–48 h peak WBC, 103/ml 13.23  4.26 11.32  5.79 <0.01
24–48 h nadir Hb, g/dl 10.96  1.49 9.89  1.72 <0.01
48–96 h peak WBC, 103/ml 12.40  4.49 9.88  4.69 <0.01
48–96 h nadir Hb, g/dl 10.71  1.51 9.41  1.80 <0.01
Post-operative peak troponin, ng/ml 6.18  4.96 1.85  2.68 <0.01
Electrocardiogram
Baseline LVH 19 (27.14) 2 (3.85) <0.01
Echocardiogram
Ejection fraction, % 58.29  10.58 54.61  14.76 0.08
Mean aortic gradient, mm Hg 43.07  12.58 45.25  16.97 0.48
Aortic valve area, cm2 0.69  0.21 0.65  0.17 0.40
Left atrial size <0.01
Mild enlargement 32 (27.35) 12 (24.00)
Moderate and severe enlargement 13 (18.30) 6 (11.53)
Diastolic function 0.93
Grade I 51 (77.27) 36 (72.00)
Grade II–III 12 (18.19) 11 (22.00)
Procedure
Blood transfusion 67 (97.10) 37 (71.15) <0.01
Complications
Required permanent pacemaker 4 (5.63) 6 (11.54) 0.39
Stroke or TIA 1 (1.41) 4 (7.69) 0.08
Renal insufﬁciency 25 (35.21) 14 (26.92) 0.57
Prolonged intubation 32 (49.25) 6 (11.54) <0.01
Bleeding 33 (49.25) 31 (62.00) 0.17
Values are n (%) or mean  SD.
Abbreviations as in Table 1.
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1517available data are limited, and the incidence of AF varies on
the basis of population, deﬁnition of AF, and monitoring
method. In the high-risk cohort of the PARTNER
(Placement of Aortic Transcatheter Valve) study, which
used an electrocardiographic core laboratory to validate AF
after TAVR and might not have included short episodes,
new-onset AF occurred in only 8.6% of patients at 30 days(2). Similarly, Motloch et al. (15) used 72-h post-
procedural monitoring and a deﬁnition of AF as episodes
lasting more than 10 min; they found new-onset AF in 5
patients (11.6%) in the TA-TAVR group versus no epi-
sodes in the TF-TAVR group. That study, however,
included patients with pre-existing AF, which was up to
32% of the TAVR group. The only prospective cohort
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1518evaluating new-onset AF in patients who underwent
TAVR due to either high or prohibitive operative risk was
recently reported by Amat-Santos et al. (6), who demon-
strated 32% of new-onset AF within 30 days after TAVR.
That study included any AF episodes that lasted more than
30 s, and all the patients were on electrocardiographic
monitoring until discharge from the hospital. By this
method, new-onset AF occurred in 6 patients (15.79%)
who underwent TF-TAVR and 38 patients (38%) who
underwent TA-TAVR (6). The results of that study were
comparable to ours with respect to the TF group (Fig. 2).
However, our TA-TAVR cohort appeared to have a much
higher incidence (up to 53%). All patients in the TA-
TAVR group were considered inoperable with a high
STS score compared with the study by Amat-Santos et al.
The higher comorbidities (STS score, 11.0  3.4 vs. 7.4 
4.8) and the older population group (age, 88  5 years vs.
79  8 years) might contribute to the higher incidence of
AF in our TA-TAVR group. The incidence of new-onset
AF in TAo-TAVR was not previously reported. The study
by Nombela-Franco et al. (7) was the only study that
included patients who underwent TAo-TAVR, reporting
12% of new-onset AF and its relation to CVA at 30 days.
However, more than two-thirds of enrolled patients un-
derwent TF-TAVR, and TAo-TAVR accounted for only
0.4% of populations. Together, these studies suggested that
the actual incidence of AF in TAVR was higher than
previously appreciated.
The development of post-operative AF is likely multi-
factorial. Potential precipitating factors can be classiﬁed as
either acute factors caused by the intervention or chronic as
related to structural heart disease and aging of the heart. In
terms of acute factors, the SAVR and different approaches
of TAVR contribute to different known factors associated
with new-onset AF after the procedures. Inﬂammatory
processes during cardiopulmonary bypass used in SAVR,
atrial inﬂammation, and transient sterile pericarditis
occurred in procedures with pericardiotomy, and high
sympathetic tone from thoracotomy was reported as the
contributing mechanism of new-onset AF (14,16–19). In
our study, procedures without pericardiotomy were associ-
ated with an 82% lower risk of new-onset AF in multivariate
analysis (Table 3). Blood transfusion was also associated
with post-operative AF, with studies reporting an 18% in-
crease in the odds for developing AF per unit of red blood
cells transfused (20–23). Although not statistically signiﬁ-
cant with multivariate analysis, patients who received blood
transfusions trended toward having a higher rate of new-
onset AF after the procedure.
Pericardiotomy appears to be the most important acute
factor associated with new-onset AF in our study. This
ﬁnding might explain the higher incidence of new-onset AF
in TA-TAVR compared with TF-TAVR in previous
studies (2,6,15). When accompanied with the report of less
complicated and faster post-operative recovery in TAo-
TAVR, compared with TA-AVR, it might support theconsideration of using TAo-TAVR as the second-line
approach when TF-TAVR is not feasible (9,24).
In terms of chronic factors, advancing age was found to be
the strongest predictor of post-operative AF (25). Associa-
tion with other risk factors, including left atrial enlargement,
body mass index, renal insufﬁciency, hypertension, diastolic
dysfunction, and history of chronic obstructive pulmonary
disease showed a large degree of variability between different
studies, which was most likely due to the different pop-
ulations (14). The signiﬁcantly higher use of calcium
channel blockers in those who developed AF might reﬂect
the higher degree of severity of hypertension, rather than the
contributing risk from medication itself. In our study, no
clinical risk factors were found to be signiﬁcantly associated
with post-operative AF.
The temporal distribution analysis showed that the ma-
jority of post-operative AF events in our patients (78.84%)
occurred in the interval between 24 and 96 h after the pro-
cedure, with the median time of onset at 53 h (range: 41 to
87 h). More than 60% of these episodes lasted less than 24 h.
The timing of onset and duration of new-onset AF were not
signiﬁcantly different among the various subgroups. These
ﬁndings were in accord with post-operative AF reported in
patients who underwent conventional SAVR. It was, how-
ever, different from the previous reports in patients who
underwent TAVR that showed a more variable time course
(6,15). All of our patients were in sinus rhythm on the 12-lead
electrocardiogram at the immediate post-operative period,
and there were no AF episodes noted during the procedure in
our patients. We hypothesized that procedural techniques
might play a role in AF occurring during the procedure.
The most concerning aspect of new-onset AF was its
relationship with CVA, particularly in the subacute period
(7), and the resulting need for anticoagulation. In our study,
all patients had a high CHADS2 and CHA2DS2-VASc
score, with a minimum of CHADS2 score of 1 (Online
Table B). Five patients in our study developed stroke or
TIA after TAVR. All patients with stroke or TIA without
new-onset AF developed the stroke within 1 week, whereas
those with a history of new-onset AF experienced the event
within the ﬁrst month of the procedure. Neither of these
2 patients was anticoagulated at the time of the stroke or
TIA diagnosis. The higher risk of new-onset AF in the TA-
TAVR group might explain the similar risk of stroke in the
TF- and TA-TAVR approaches at 30 days (7). Although 1
potential mechanism for stroke risk in the TF-TAVR cohort
might be manipulation of the delivery system through the
diseased aorta, a contributing factor in TA-TAVR might be
new-onset AF. These ﬁndings highlighted the importance
of prevention, prompt diagnosis, and treatment in the
patients who develop new-onset AF. Nonetheless, using
anticoagulation frequently poses a signiﬁcant clinical prob-
lem due to high risk of bleeding events, either from the
access site or from the combined use of dual antiplatelet
therapy. Further evaluation of preventive strategies in those
patients at higher risk of bleeding post-TAVR is warranted.
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1519Study limitations. This study was limited by its small
population size, single-center source, and retrospective
nonrandomized design. The lack of pre-procedural electro-
cardiographic monitoring and the nature of being a referral
center might have led to underestimation of the pre-existing
paroxysmal atrial arrhythmia. Interobserver variability of
echocardiographic interpretation remained an issue, espe-
cially subjective evaluation for severity of pathology.
Obtaining the multidimensional measurement and volume
of the left atrium might provide a better accuracy and
reproducibility of its relation with new-onset AF. In addi-
tion, the incidence of new-onset AF following AVR was
subject to underestimation, on the basis of the limitations
imposed by routine 2- or 4-h post-procedure printouts of
monitoring tracings and lack of extended monitoring after
discharge. Although a valid concern, this limitation likely
had a small effect on the basis the time and duration of the
majority of AF events in this study (Fig. 2). All treatment
data in our study were observational, so it should only be
used for hypothesis-generating purposes, with limited value
due to the heterogeneity of therapeutic strategies. For the
diagnosis of stroke or TIA, no routine imaging studies were
performed, and the diagnostic investigations were performed
on the basis of clinical ﬁndings.
Conclusions
Despite its limitations, this was the ﬁrst study to evaluate the
incidence of new-onset atrial ﬁbrillation among elderly pa-
tients with degenerative AS who underwent SAVR
compared with different TAVR approaches. New-onset AF
was found in more than 40% of patients, with the highest
incidence in the surgical group, followed by TA-, TAo-, and
TF-TAVR approaches, respectively. Pericardiotomy
appeared to be the most important technical factor associ-
ated with new-onset AF. Randomized controlled trials
studying the impact of access site on the incidence of AF in
TAVR are warranted.
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